Overview

A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

Status:
RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
Phase:
PHASE2
Details
Lead Sponsor:
Upstream Bio Inc.